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Abstract
Background: Ubiquitin Carboxyl-Terminal Hydrolase-L1 (UCH-L1) is a deubiquitinating enzyme that is highly expressed
throughout the central and peripheral nervous system and in cells of the diffuse neuroendocrine system. Aberrant
function of UCH-L1 has been associated with neurological disorders such as Parkinson’s disease and Alzheimer’s disease.
Moreover, UCH-L1 exhibits a variable expression pattern in cancer, acting either as a tumour suppressor or promoter,
depending on the type of cancer. In non-small cell lung carcinoma primary tumour samples, UCH-L1 is highly
expressed and is associated with an advanced tumour stage. This suggests UCH-L1 may be involved in oncogenic
transformation and tumour invasion in NSCLC. However, the functional significance of UCH-L1 in the progression of
NSCLC is unclear. The aim of this study was to investigate the role of UCH-L1 using NSCLC cell line models and to
determine if it is clinically relevant as a prognostic marker for advanced stage disease.
Methods: UCH-L1 expression in NSCLC cell lines H838 and H157 was modulated by siRNA-knockdown, and the
phenotypic changes were assessed by flow cytometry, haematoxylin & eosin (H&E) staining and poly (ADP-ribose)
polymerase (PARP) cleavage. Metastatic potential was measured by the presence of phosphorylated myosin light chain
(MLC2). Tumour microarrays were examined immunohistochemically for UCH-L1 expression. Kaplan-Meier curves were
generated using UCH-L1 expression levels and patient survival data extracted from Gene Expression Omnibus data files.
Results: Expression of UCH-L1 was decreased by siRNA in both cell lines, resulting in increased cell death in H838
adenocarcinoma cells but not in the H157 squamous cell line. However, metastatic potential was reduced in H157
cells. Immunohistochemical staining of UCH-L1 in patient tumours confirmed it was preferentially expressed in
squamous cell carcinoma rather than adenocarcinoma. However the Kaplan-Meier curves generated showed no
correlation between UCH-L1 expression levels and patient outcome.
Conclusions: Although UCH-L1 appears to be involved in carcinogenic processes in NSCLC cell lines, the absence
of correlation with patient survival indicates that caution is required in the use of UCH-L1 as a potential prognostic
marker for advanced stage and metastasis in lung carcinoma.
Background
Ubiquitination is a highly diverse and complex post-
translational modification responsible for controlling
protein expression and activity in a vast array of cellular
processes such as proteasomal degradation, cell cycle
regulation, protein trafficking, inflammation and DNA
repair [1,2]. Removal of ubiquitin via the action of deu-
biquitinating enzymes (DUBs) is integral to the regula-
tion of the ubiquitin system, hence the importance of
these enzymes in the maintenance of protein expression
and function. There are 5 classes of DUBs and Ubiquitin
Carboxyl Terminal Hydrolase-L1 (UCH-L1), a member
of the UCH family, catalyses the hydrolysis of ubiquitin
from ubiquitin precursors and from ubiquitinated pro-
ducts following proteasomal degradation of polyubiquiti-
nated proteins [3-6]. Therefore UCH-L1 is responsible
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for conserving the cellular pool of ubiquitin and it has
also been implicated in cellular pathways such as prolif-
eration, apoptosis and cell migration [7]. A unique char-
acteristic of UCH-L1 is its ability to act as an ubiquitin
ligase in dimeric form, in contrast to acting as a hydro-
lase in its monomeric form [8].
UCHL-1 is highly expressed in the central and periph-
eral nervous system, reproductive tissue and neuroendo-
crine (NE) cells, although it is expressed in most adult
tissues [9,10]. In both reproductive organs and nervous
tissue, UCH-L1 promotes apoptosis. In testicular germ
cells UCH-L1 expression is responsible for an early apop-
totic wave during spermatogenesis but tight regulation of
UCH-L1 is important as high levels cause excessive apop-
tosis in the ovaries and testes of transgenic mice [5,11].
In retinal neurons the regulation of intracellular ubiquitin
by UCH-L1 alters the stability of pro-apoptotic and anti-
apoptotic proteins with a substantial increase in Bcl-2
and XIAP levels in UCH-L1 null mice compared to
UCH-L1 wildtype [12,13]. Aberrant UCH-L1 function in
neurons manifests as neurological diseases, such as Par-
kinson’s disease (PD), where dysfunctions of the ubiqui-
tin-proteasome system allow the accumulation of a-
synuclein, which is important in the pathology of the dis-
ease. Mutations in UCH-L1 have been detected in cases
of familial PD. In particular the I93 M amino-acid substi-
tution has been linked to a rare inherited form of PD
known as PARK5 [5,14], whereas the S18Y polymorph-
ism reduces susceptibility to PD [15].
In cancer, UCH-L1 exhibits highly variable expression
patterns seemingly in a tumor-specific manner. UCH-L1
can act as a tumor-suppressor and is silenced in ovarian
[16], hepatocellular [9,17], renal cell [17,18], head and
neck [19] and oesophageal carcinomas [20], when com-
pared to normal tissue. The silencing in many cases is
due to hypermethylation of the UCH-L1 promoter
region [16,20-22]. On the contrary, UCH-L1 is over-
expressed in neuroblastoma [23], lung carcinoma, inde-
pendent of neuronal differentiation [24], myeloma [25],
prostate carcinoma [26], osteosarcoma [27] and pancrea-
tic carcinoma [28]. Several types of cancer present con-
tradictory results in relation to UCH-L1 expression
patterns and this is the case in both colorectal and
breast carcinoma [16,29-31].
In non-small cell lung carcinoma (NSCLC) UCH-L1 is
consistently highly expressed in both cell lines and pri-
mary tumour samples when compared to normal lung
tissue where the expression of UCH-L1 is confined
solely to cells of the neuroendocrine (NE) system. The
presence of high levels of UCH-L1 has also been asso-
ciated with an advanced tumor stage suggesting a possi-
ble role of UCH-L1 in oncogenic transformation and
tumor invasion in NSCLC [32,33]. A correlation has
been found between UCH-L1 expression and
histological type, with squamous cell carcinomas expres-
sing the protein more frequently than adenocarcinomas
[24,34].
The distinction between different types of NSCLC was
until quite recently, clinically unimportant. It was neces-
sary only to decide if a patient had NSCLC or small cell
carcinoma, a determination which can be made robustly
on morphology. With the development of drugs such as
Pemetrexed (Alimta™), which shows more activity
against non-squamous NSCLC and Bevacizumab (Avas-
tin™), which is contraindicated for use in squamous cell
carcinoma, the further classification of NSCLC type is
now the clinical standard. The distinction is made on
the basis of morphology, histochemistry (mucin staining
with Alcian blue/Periodic acid Schiff) and immunohisto-
chemistry for thyroid transcription factor 1 (TTF-1),
cytokeratins (CK) 5/6 and p63 amongst other possible
combinations. Squamous differentiation is indicated by
positivity with CK5/6 and p63 whilst TTF-1 is negative
[35]. Therefore, the differential expression of UCH-L1
in NSCLC has a particular relevance given this impetus
for classification of tumor type.
To establish whether UCH-L1 plays an important role
in the pathogenesis of lung carcinoma we used two
NSCLC cell lines of different subtypes to investigate the
phenotypic effects observed following silencing of UCH-
L1. We found that UCH-L1 expression increases apop-
totic resistance in the adenocarcinoma cell line (H838)
and promotes cell migration in the H157 squamous cell
carcinoma cell line. Also, in NSCLC tumor samples we
showed that UCH-L1 is preferentially expressed in squa-
mous cell carcinoma. To examine the importance of
UCH-L1 in patient samples we analyzed NSCLC patient
survival data but despite the oncogenic role found in
the NSCLC cell lines, no correlation between UCH-L1
expression and survival was evident.
Methods
Cell Culture
All cell lines were maintained in RPMI 1640 medium
containing 10% fetal bovine serum (PAA, Pasching, Aus-
tria), 100 U/ml penicillin and 100 μg/ml streptomycin
(Invitrogen, Paisley, UK), except BEAS-2B, MPP-89 and
REN cells which were maintained in GIBCO® F12
(Ham) Nutrient Mixture (Invitrogen), supplemented
with 10% FBS, 1% Penicillin/Streptomycin, 1% L-gluta-
mine and 1% Non-Essential Amino Acids. The cells
were grown in a humidified incubator (Sanyo, San
Diego, CA) at 37°C with 5% CO2.
Quantitative PCR
UCH-L1 mRNA expression in parental and UCH-L1
siRNA-treated H157 and H838 cells was measured by
quantitative-PCR (q-PCR). Primers and probes for
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UCH-L1 (assay ID: Hs00188233_m1) and 18S RNA
internal control (assay ID: Hs99999901_s1) were
obtained from Applied Biosystems (Foster City, CA).
Reactions were carried out on the ABI Prism 7500 sys-
tem equipped with a 96-well thermal cycler as pre-
viously described [36]. Briefly, total RNA was extracted
from cells with TRIzol (Invitrogen) and cDNA was
obtained by reverse transcription. Data were collected
and analyzed with Sequence Detector 7500 System v2.1
software (Applied Biosystems) and relative gene expres-
sion was calculated using the ΔΔCt method.
Sequencing of UCH-L1 gene
DNA was extracted from each cell line using the
DNeasy Blood and Tissue Kit (Qiagen, West Sussex,
UK). PCR-directed sequencing was performed using
standard protocols (primers available on request). The
DNA sequencing data was viewed and analysed using
Chromas Lite software (Technelysium Pty Ltd., Shan-
non, Ireland) and SeqMan™ II software (DNA Star,
West Lothian, UK).
Immunoblotting
Western blot analysis was used to detect the expression
level of proteins as previously described [37]. Primary
antibodies used were anti-UCH-L1, anti-Phospho-
MLC2, anti-MLC2 (New England Biolabs, Hitchin, UK),
anti-PARP (eBioscience, Hatfield, UK) and anti-b-actin
(Sigma-Aldrich, Dorset, UK).
siRNA transient transfection
UCH-L1 siRNA (synthesized by Dharmacon, Thermo
Fisher Scientific, Loughborough, UK) was transiently
transfected into H838 and H157 cells in 6-well plates
using siPORT NeoFX transfection agent according to
the manufacturer’s recommendations (Ambion, Applied
Biosystems). Briefly, prior to the transfection, cells were
trypsinised then resuspended in media without antibio-
tics at a cell density of 1 × 105/ml. For each transfection
reaction, 5 μl of siPORT NeoFX reagent was applied to
95 μl of Opti-MEM medium (Invitrogen), incubated at
room temperature for 10 min, then mixed with an equal
volume of UCH-L1 siRNA solution (to give a final con-
centration of 10 nM). After incubation at room tem-
perature for 10 min, the siRNA transfection complexes
were dispersed into 6-well plates and overlaid by cell
suspensions, gently mixed and incubated for 48 to 72 hr
at 37°C, 5% CO2. Transfection efficiency was assessed by
q-PCR and Western blot.
Phase-contrast microscopy
Phase-contrast microscopy with a Zeiss Axiovert 200
phase-contrast microscope (Carl Zeiss Microimaging
Inc., Welwyn Garden City, UK) equipped with an Orca
camera (Hamamatsu Photonics, Hamamatsu City,
Japan) was used to observe the morphological changes
in H838 cells 48 hr post-transfection of UCH-L1
siRNA.
Haematoxylin & eosin staining and light microscopy
Transiently transfected H838 cells were grown on cover-
slips. At 48 hr after transfection, the cells were fixed in
90% ethanol, stained with haematoxylin & eosin (H&E)
and viewed under light microscope for signs of apopto-
sis. The cells with abnormal nuclear features such as a
fragmented nucleus or breakdown of the nuclear mem-
brane were classified as apoptotic. For each slide, the
numbers of apoptotic cells in 20 different fields at 250×
magnification were counted.
Flow Cytometry
At 72 hr post-transfection cells were harvested by tryp-
sinisation and fixed by ice-cold 70% ethanol for 1 hr.
The fixed cells were washed twice with PBS and stained
with 0.5 ml of 40 μg/ml propidium iodide (PI) at 37°C
for 30 min protected from light. The PI-stained samples
were analyzed by the BD™ LSR II FACS instrument
and the BD™ FACS Flow Supply System (BD Bios-
ciences, CA) and a total of 10,000 events were analyzed.
The hypodiploid sub-population in sub-G1/G0 phase
was regarded as apoptotic cells and the percentages of
these cells were calculated using the BD™ FACS Diva
software v.6.1.2.
Immunohistochemistry of cell lines and patient samples
Formalin-fixed paraffin wax-embedded cell blocks of
H157, H838 and BEAS-2B cells and paraffin wax
embedded sections from 140 samples of NSCLC were
stained for UCHL-1 expression. Briefly, sections were
pre-treated in a 750 W microwave oven (0.1 M citrate
buffer, pH 6.0) for 22 minutes, cooled rapidly, washed in
Tris-buffered Saline and were incubated in mouse anti-
UCHL-1 (NCL-PGP9.5, 1:100; Novocastra, Newcastle
Upon Tyne, UK) overnight at 4°C. Localisation was
achieved using Envision peroxidise kit as recommended
by the manufacturer (Dako, Ely, UK). All sections were
counterstained in Meyer’s haematoxylin. Immunoreac-
tivity was assessed by two observers and percentage
positive agreed. A cut-off value of 10% was used for
UCH-L1 results. Selected sections were incubated with
mouse immunoglobulin as negative controls. All tissues
were used under regional ethical permission (ORECNI,
08/NIR03/73) and sourced from the Belfast Health &
Social Care Trust, ISU Abxis Co (Cepheid, Stretton,
UK) and US Biomax Inc (Insight Biotechnology Ltd,
Wembley, UK).
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Analysis of UCH-L1 expression and NSCLC patient survival
in publicaly available datasets
Three relevant publicaly available lung cancer datasets
(GSE13213, GSE3141 and GSE13213) which contained
whole-genome profiles and associated patient outcome
data were identified in the Gene Expression Omnibus
(GEO) database repository. GSE13213 consisted of
whole-genome expression profiles of 117 adenocarci-
noma samples with the associated outcome data of
“days survival”. GSE3141 consisted of 111 primary lung
tumour samples with associated survival data stated in
“months survival” and GSE8894 contained gene expres-
sion profiles from primary tumours from 138 lung can-
cer patients with associated “recurrence free survival
(months)” outcome data. Expression profiles for
GSE13212 were generated using the Agilent-014850
Whole Human Genome Microarray 4 × 44 K G4112F
platform which contains 1 probe for the UCH-L1 gene
(A_23P132956). For both GSE3141 and GSE8894 data-
sets, gene expression profiles were generated using Affy-
metrix Human Genome U133 Plus 2.0 Array which
contains 2 probesets for the UCH-L1 gene (1555834_at,
201387_s_at). The Series Matrix files were downloaded
from GEO for all 3 datasets. Normalized expression
data and associated outcome data were imported into
the Partek Genomics Suite (Partek Inc, St Louis, MO).
Patients were separated into quartiles based on expres-
sion levels of the UCH-L1 gene for each dataset. The
survival times for each quartile were compared using
Kaplan-Meier survival analysis and the log-rank test.
Statistical Analysis
All experiments were carried out with a minimum of n
= 3. Intergroup comparisons were made by Student’s t
test with P < 0.05 considered statistically significant.
Results
Expression of UCH-L1 in non-small cell lung carcinoma
lines
To identify a cell line model exhibiting high UCH-L1
expression that could be modulated for further investi-
gations a range of human non-small cell lung carcinoma
cell lines was surveyed for UCH-L1 expression by q-
PCR and immunoblotting and compared to a normal
lung cell line BEAS-2B (Figure 1). This revealed several
cell lines (H157, H460 and H838) with high levels of
UCH-L1 mRNA expression (Figure 1A). Interestingly,
the cell lines with elevated UCH-L1 expression had dif-
fering origins; H460 is a large cell lung carcinoma while
H157 is of squamous cell origin and H838 is an adeno-
carcinoma established from a metastatic lymph node.
The level of UCH-L1 protein was found to reflect
mRNA expression shown in Figure 1B &1C, with H157,
H460 and H838 exhibiting abundant protein production.
Sequencing the UCH-L1 gene in these different cell
lines failed to detect any mutations. Cell blocks of H157
and H838 cells were also stained by immunohistochem-
istry for UCH-L1 expression and both stained positive
for the protein (Figure 2A and 2B).
Silencing of UCH-L1 expression in the H838
and H157 cell lines
To establish if elevated UCH-L1 levels contribute to
lung carcinogenesis, expression in H157 and H838 cells
was silenced using siRNA and any subsequent phenoty-
pic changes were investigated. UCH-L1 mRNA was sub-
stantially down-regulated in H838 cells at 24 hr post-
transfection and remained decreased at 96 hr post-trans-
fection (Figure 3A). Immunoblotting confirmed UCH-L1
protein was significantly reduced at 24 hr post-
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Figure 1 UCH-L1 expression is higher in NSCLC cell lines than
in normal lung cells. A. Fold change of UCH-L1 mRNA in lung
cancer cell lines compared to the normal lung cell line BEAS-2B (n
= 3). B. Densitometry of the level of UCH-L1 protein detected by
Western Blot relative to the level of b-actin detected (n = 3). C.
Western Blot detection of UCH-L1 protein and b-actin loading
control in different cell lines. Lanes as follows: 1 = H23, 2 = H157, 3
= H460, 4 = H838, 5 = BEAS-2B, 6 = MPP-89, 7 = REN, 8 = SKMES, 9
= UT-7.
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Figure 2 Immunohistochemistry showing UCH-L1 positive cells
in H157 and H838 cells. Brown staining indicates the presence of
UCH-L1 in H157 (A) and H838 (B) cells. (Scale bar is equivalent to
15 μm).
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transfection and by 72 hr the protein was undetectable
in both H838 cells (Figure 3B) and H157 cells
(Figure 3C).
UCH-L1 supports cell survival in H838 cells
Assessment of H838 and H157 cells exhibiting reduced
UCH-L1 protein levels by phase-contrast microscopy
revealed morphological changes in the UCH-L1 siRNA-
treated H838 cells compared to scrambled siRNA- trea-
ted and untreated control cells, whereas no difference
was observed between UCH-L1 siRNA-treated H157
cells and control H157 cells. Normally the parental H838
cells were rounded in shape and uniform in size, but cells
with reduced UCH-L1 expression were irregular in
shape, variable in size, and present at a much lower den-
sity. H838 cells with low levels of UCH-L1 were also less
flattened to the surface, possibly signifying they were
becoming detached, a characteristic of apoptotic cells
(Figure 4A). Therefore untreated and treated H838 cells
were stained with H&E to compare the number of apop-
totic cells. Definite apoptotic changes were observed in
the UCH-L1 siRNA-treated cells (Figure 4B). To quantify
the differences in apoptosis between the siRNA-treated
and untreated cells, the number of apoptotic cells as
characterised by fragmentation of the nucleus or break-
down of the nuclear envelope were counted in 20 fields
of view at 250× magnification. A large increase in the
number of apoptotic cells was observed in H838 cells
with reduced UCH-L1 expression, which was statistically
significant with a p-value of < 0.01 (Figure 4C).
Since apoptosis results in an increased number of cells
in the sub G1/G0 phase of the cell cycle, flow cytometry
was used to quantify this specific population of cells.
H838 cells with reduced UCH-L1 were observed to have
a greater proportion, around 30%, of cells in sub G1/G0
phase which was statistically significant, and there was
an overall decrease in the total cell population which
correlates with an increased rate of apoptosis (Figure 5A
&5B). To further confirm apoptosis was present, PARP
cleavage was measured by immunoblotting. Cleavage of
the PARP protein into two fragments, an early indicator
of apoptosis, was only apparent in H838 cells post
UCH-L1 siRNA knock-down (Figure 5C). Studying cell
proliferation using CyQUANT® assays at two different
time points post-transfection indicated that loss of
UCH-L1 expression did not affect cell proliferation
(Additional File 1). In contrast, H157 cells did not exhi-
bit apoptotic features when UCH-L1 expression was
reduced and no reduction in proliferation was observed
as measured by Ki67 staining (data not shown).
UCH-L1 promotes cell migration in H157 cells
Although loss of UCH-L1 expression did not affect cell
viability in H157 cells, it could influence the metastatic
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Figure 3 Knockdown of UCH-L1 in H838 and H157 cells by siRNA. A. Percentage knockdown of UCH-L1 mRNA in H838 cells at 24 hr, 48 hr,
72 hr and 96 hr post-transfection compared to time-matched control. B & C. Immunoblot detection of UCH-L1 protein expression at 24 hr, 48
hr and 72 hr post-transfection in H838 cells (B) and H157 cells (C). (U = UCH-L1 siRNA, S = Scrambled siRNA, C = Untreated control).
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process since previous studies have implicated UCH-L1
in metastasis of tumour cells [17,26,30]. Cell migration
assays can be used as an indicator of metastatic poten-
tial, therefore the protein level of phosphorylated myo-
sin light chain (MLC2), a surrogate marker for
migratory capacity, was measured by immunoblotting. A
reduction in phosphorylated MLC2 in H157 cells post
siRNA transfection was detected (Figure 6A), whereas
total MLC2 levels remained constant (Figure 6A). Statis-
tical analysis showed the level of phospho-MLC2 was
significantly reduced in the siRNA treated cells com-
pared to those treated with scrambled siRNA but less so
when compared to the untreated control H157 cells
(Figure 6B and 6C). It was not possible to analyze the
migratory capacity of H838 cells as the cells following
UCH-L1 knockdown were of too poor a quality to give
reproducible results.
Relevance of UCH-L1 over-expression in NSCLC patient
tumour samples
To establish if UCH-L1 is consistently overexpressed in
NSCLC tumour samples 140 cases (85 squamous cell car-
cinomas and 55 adenocarcinomas) were screened for
UCH-L1 positivity by immunohistochemistry (Figure 7A
and 7B). Overexpression of UCH-L1 was detected in 47
cases (34.3%) and among these positive cases 37 were
squamous cell carcinoma and 10 cases were adenocarci-
noma hence UCH-L1 was correlated with histological type
(r = 0.262).
UCH-L1 expression does not correlate with long term
survival
To investigate if the potential oncogenic role of UCH-L1
observed in the cell line model is reflected in patients,
Kaplan-Meier plots were generated for NSCLC patients
A
B
i) iii)ii)
i) iii)ii)
C
Figure 4 Reduced UCH-L1 expression alters morphology of H838 cells and increases the number of apoptotic cells. A. Phase-contrast
microscopy photographs of i) non-transfected H838 cells; ii) scrambled siRNA-treated H838 cells; iii) UCH-L1 siRNA-treated H838 cells. B. H & E
staining of i) non-transfected H838 cells; ii) scrambled siRNA-treated H838 cells; iii) UCH-L1 siRNA-treated H838 cells. (Scale bar is equivalent to 15
μm). C. Number of apoptotic cells counted in 20 fields of H&E stained slides at 250× magnification.
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based on UCH-L1 expression. To do this three microarray-
based gene expression studies with associated patient out-
come data (accession numbers GSE13213, GSE8894 and
GSE3141) were identified that were available from the
NCBI’s Gene Expression Ombnibus (GEO). Normalized
microarray data and phenotype data were downloaded and
samples were separated into quartiles according to UCH-
L1 expression levels. Kaplan-Meier survival analysis,
including the log-rank test, was performed on each of the
quartiles. No significant difference in survival was observed
between the quartiles for all three datasets (Figure 8).
Kaplan-Meier survival analysis was also performed on
patients separated into above and below the median and
on the upper and lower quartiles for UCH-L1 expression.
In all 3 datasets no significant difference was observed in
any of the comparisons (Additional files 2, 3 and 4).
Discussion
The present study indicates that UCH-L1 is highly
expressed in lung squamous cell carcinoma, and NSCLC
cell line studies show that increased UCH-L1 expression
causes apoptotic resistance in H838 adenocarcinoma
cells and a greater capacity for cell migration in the
H157 squamous cell carcinoma cell line. However,
despite the oncogenic effects of UCH-L1 observed in
NSCLC cell lines, its expression does not appear to
affect patient survival in NSCLC.
Our findings reveal that 4 of 5 NSCLC cell lines ana-
lyzed exhibit statistically significant increases in wild
type UCH-L1 expression when compared to the normal
lung cell line and approximately one third of 140
NSCLC samples (stage II/III) stain positive for UCH-L1
by immunohistochemistry. This confirms previous
reports that UCH-L1 is highly expressed in NSCLC cell
lines and primary tumours. UCH-L1 staining also corre-
lates with histology as squamous cell carcinomas express
the protein more frequently than adenocarcinomas.
Although Sasaki et al [34] found no such association,
our results are in agreement with a previous study in
which 72% squamous cell carcinoma tumours were posi-
tive for UCH-L1 in comparison to 41% in the adenocar-
cinoma subset [24].
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Figure 5 UCH-L1 expression in H838 cells confers apoptotic resistance measured by flow cytometry and PARP cleavage. A. Comparison
of cell cycle analysis of propidium iodide stained untreated H838 cells (Panel i), scrambled siRNA-treated H838 cells (Panel ii) and H838 cells
treated with UCH-L1 siRNA (Panel iii). The percentage of cells in sub G1/G0 are shown above each panel. B. The percentage of cells in sub
G1/G0 phase of the cell cycle in each treatment group for 3 independent experiments are shown graphically. C. Immunoblot showing PARP
cleavage in siRNA-treated and parental H838 cells.
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The functional role of UCH-L1 in lung tumourigenesis
however remains elusive, therefore following confirma-
tion of high UCH-L1 expression we examined the
phenotypic effects in NSCLC cell lines. The expression
of UCH-L1 was reduced using siRNA in both squamous
cell carcinoma (H157) and adenocarcinoma (H838) cell
lines. Knockdown of UCH-L1 in H838 cells shows mor-
phological differences indicative of apoptosis and cell
death was confirmed by H&E staining, cell cycle analysis
and the presence of PARP cleavage. Although other stu-
dies have not examined the effect of UCH-L1 specifi-
cally in H838 cells, UCH-L1 has been associated with
apoptosis in several cases. In neuronal cells and testicu-
lar germ cells UCH-L1 is viewed as an apoptosis-pro-
moting protein due to its role in balancing the levels of
pro-apoptotic and anti-apoptotic proteins [9,11,12]. In
contrast, the current investigation shows that UCH-L1
increases apoptotic resistance, confirming a number of
recent reports [15,38]. Treatment of neuroblastoma cells
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Figure 6 Lower levels of UCH-L1 decrease phosphorylation of MLC2 in H157 cells. A. Immunoblot of pMLC-2 protein, total MLC2, UCH-L1
knockdown and b-actin loading control in H157 cells post siRNA treatment. B. Densitometry analysis for 3 sets of blots exhibiting UCH-L1
protein level in untreated H157 cells and cells treated with either scrambled siRNA or UCH-L1 siRNA. UCH-L1 protein levels in H157 cells were
normalized to b-actin. C. Densitometry analysis for 3 sets of blots exhibiting MLC2 phosphorylation in untreated H157 cells and cells treated with
either scrambled siRNA or UCH-L1 siRNA. Phospho-MLC2 protein levels in H157 cells were normalized to b-actin.
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Figure 7 UCH-L1 expression in adenocarcinoma and squamous
cell carcinoma. A. Squamous cell carcinoma stained positive (i) and
negative (ii) for UCH-L1. B. Adenocarcinoma positive (i) and
negative (ii) for UCH-L1 expression. Brown staining indicates the
presence UCH-L1. (Scale bar is equivalent to 25 μm).
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Figure 8 UCH-L1 expression does not correlate with patient survival. A. Kaplan-Meier analysis for patients within the GSE13213 dataset. The
UCH-L1 gene was represented by a single probeset (A-23P132956). The time variable was “days survival” and the event variable was “alive or
dead”. B &C. Kaplan-Meier analysis for patients within the GSE3141 dataset. The time variable stated was “months survival” and the event
variable was “dead or alive”. The UCH-L1 gene was represented by 2 separate probesets (1555834_at and 201387_s_at). Individual Kaplan-Meier
plots were generated for each of the probesets (B-probeset 1555834_at and C-probeset 201387_s_at). D & E. Kaplan-Meier analysis for
patients within the GSE8894 dataset. The time variable used was “recurrence free survival” and the event variable was “recurrence or non-
recurrence”. The UCH-L1 gene was represented by 2 separate probesets (1555834_at and 201387_s_at). Individual Kaplan-Meier plots were
generated for each of the probesets (D-probeset 1555834_at and E-probeset 201387_s_at).
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with an UCH-L1 inhibitor was shown to cause apopto-
sis, mediated through decreased activity of the protea-
some and accumulation of highly ubiquitinated proteins.
This caused endoplasmic reticulum stress in the neuro-
blastoma cells which eventually led to the initiation of
cell death [38]. Likewise, the up-regulation of UCH-L1
in human hepatoma cells following low dose UV irradia-
tion was reported to be involved in the regulation of cell
death by inhibition of p53-mediated apoptosis; hence in
both these cases UCH-L1 was demonstrated to be an
“apoptosis-evading protein” [39], as in the present study.
In contrast to H838 cells, our study reveals UCH-L1
knockdown causes no difference in morphology, apopto-
sis or proliferation in H157 cells but does reduce the
capacity for cell migration. MLC2, a protein responsible
for cell movement, is phosphorylated during cell inva-
sion [40]. In this present study it was shown that
reduced expression of UCH-L1 in H157 cells led to
decreased phosphorylation of MLC2, suggesting that
UCH-L1 may be involved in tumour cell migration. This
challenges the findings of a recent study in which treat-
ment of H157 cells with UCH-L1 siRNA resulted in
increased apoptosis and inhibition of proliferation [33].
Conversely, we observed no morphological differences
in H157 cells and no effect on proliferation (measured
by Ki67 staining) when UCH-L1 expression was
knocked down. In support of our observations, Kim et
al [32] demonstrated no effect on any phase of the cell
cycle but UCH-L1 expression increased invasive capacity
of H157 cells as measured by both Matrigel invasion
assay and wound healing assays. However, Kim et al
[32] used a different system that utilized an inducible
lentiviral vector expressing shRNA rather than oligonu-
cleotide transfection of siRNA.
Taken together our results suggest that in addition to
the correlation of UCH-L1 expression with histological
type, the functional effects of UCH-L1 on NSCLC cells
may also be subtype-dependent. Analysis of UCH-L1 in
the large cell carcinoma cell line H1299 presents yet
another different role for this protein in NSCLC since
UCH-L1 was found to be antiproliferative in this case
and the authors concluded that it is expressed as a
response to tumour growth [41].
Our cell line studies suggest that UCH-L1 expression
may be important in the pathogenesis of lung cancer. In
vivo studies of UCH-L1 expression in the lung have also
demonstrated a role for UCH-L1 in lung carcinogenesis
in two separate reports. When BALB/C nude mice were
injected with UCH-L1-expressing metastatic melanoma
cells, black melanoma colonies were generated in the
lungs but when melanoma cells treated with UCH-L1
siRNA were introduced there was a significant decrease
in the number of metastatic lung colonies [32]. Addi-
tionally, Hussain et al [3] demonstrated the spontaneous
development of lung tumours in an UCH-L1-overex-
pressing transgenic mouse model.
To assess the relevance of UCH-L1 in patient samples
we looked at whether high or low UCH-L1 expression
resulted in any difference in survival status of NSCLC
patients. Despite the evidence supporting a role for
UCH-L1 in lung carcinogenesis in the cell line study,
UCH-L1 status was not significantly associated with
patient outcome. This was particularly surprising con-
sidering high UCH-L1 expression in NSCLC was pre-
viously correlated with an advanced tumour stage.
However, Sasaki et al [34] also failed to find a link with
survival. Therefore, although cell line models seem to
indicate an oncogenic role of UCH-L1 this does not
appear to translate into patient samples.
Conclusions
In conclusion, this study shows the expression of UCH-
L1 in NSCLC is variable and dependent on histological
type. In cell line models UCH-L1 appears to have an
oncogenic role in NSCLC leading to increased apoptotic
resistance in H838 adenocarcinoma cells and a greater
capacity for migration in the squamous cell carcinoma
cell line (H157).
Despite the promising observations in the NSCLC cell
lines following UCH-L1 knockdown, translation to the
clinical setting did not indicate any correlation with
patient survival. Thus caution is required when using
UCH-L1 as a prognostic marker in isolation for advanced
stage and metastasis in lung carcinoma as other factors
may be involved. Clearly further investigation would be
required to establish whether UCH-L1 is part of a path-
way that influences prognosis in lung cancer.
Additional material
Additional file 1: Loss of UCH-L1 expression did not affect cell
proliferation of H838 cells. CyQUANT®® assays were performed at two
different time points of 24 and 48 hr post-transfection with UCH-L1
siRNA in H838 cells. The results from 3 experiments are shown
graphically. Statistical analysis showed no significant difference between
UCH-L1 siRNA-treated and controls.
Additional file 2: Kaplan-Meier analysis in the GSE13213 dataset
based on UCH-L1 expression. A. Kaplan-Meier analysis for patients
separated into above and below the median of UCH-L1 expression in
the GSE13213 dataset. B Kaplan-Meier analysis for patients separated into
quartiles based on UCH-L1 expression. The first and fourth quartiles are
included in the graph. The UCH-L1 gene is represented by a single
probe (A-23P132956).
Additional file 3: Kaplan-Meier analysis in the GSE3141 dataset
based on UCH-L1 expression represented by probesets 1555834_at
and 201387_s_at. A. Kaplan-Meier analysis for patients separated into
above and below the median expression of UCH-L1 based on probeset
1555834_at signal intensities. B. Kaplan-Meier analysis for patients
separated into quartiles based on UCH-L1 expression represented by
probeset 1555834_at. The first and fourth quartiles are included in the
graph. C. Kaplan-Meier analysis for patients separated into above and
below the median expression of UCH-L1 based on probeset 201387_s_at
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signal intensities. D. Kaplan-Meier analysis for patients separated into
quartiles based on UCH-L1 expression represented by 201387_s_at. The
first and fourth quartiles are included in the graph.
Additional file 4: Kaplan-Meier analysis in the GSE8894 dataset
based on UCHL-1 expression represented by 2 probesets
1555834_at and 201387_s_at. A. Kaplan-Meier analysis for patients
separated into above and below the median expression of UCH-L1
based on probeset 1555834_at signal intensities. B. Kaplan-Meier analysis
for patients separated into quartiles based on UCH-L1 expression
represented by probeset 1555834_at. The first and fourth quartiles are
included in the graph. C. Kaplan-Meier analysis for patients separated
into above and below the median expression of UCH-L1 based on
probeset 201387_s_at signal intensities. D. Kaplan-Meier analysis for
patients separated into quartiles based on UCH-L1 expression
represented by 201387_s_at. The first and fourth quartiles are included in
the graph.
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